Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIPAC for Peritoneal Metastasis of Colorectal Cancer
NCT07349043Phase 1Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jan 2026
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of mitomycin c and raltitrexed in colorectal cancer (CRC) (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoints: Dose-Limiting Toxicity at 4 weeks, Maximum Tolerated Dose at 4 weeks and 1 more. Started Jan 2026; status: recruiting.
02
Drugs
mitomycin craltitrexed
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07349043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07349043.